May 25, 2023 11:15 AM EDTUpdated 11:37 AM
R&D

BioX­cel looks to ex­pand la­bel to at-home use for lead psych drug. Ini­tial da­ta are mixed

Lei Lei Wu

News Reporter

BioX­cel re­port­ed Thurs­day morn­ing that Igal­mi, a drug ap­proved to treat ag­i­ta­tion in pa­tients with cer­tain psy­chi­atric dis­or­ders …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

It's been three months with­out a biotech IPO

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

A service from the Financial Times